Cyclerion Therapeutics Inc (CYCN) NPV

Sell:$3.09Buy:$3.16$0.24 (7.97%)

Prices delayed by at least 15 minutes
Sell:$3.09
Buy:$3.16
Change:$0.24 (7.97%)
Deal now
Prices delayed by at least 15 minutes
Sell:$3.09
Buy:$3.16
Change:$0.24 (7.97%)
Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

Cyclerion Therapeutics, Inc. is a biopharmaceutical company dedicated to identifying, developing, and delivering therapies for central nervous system (CNS) diseases. The Company is focused on building a pipeline with therapeutics to treat certain neuropsychiatric diseases. It is focused on an individualized therapy for treatment-resistant depression (TRD) - a condition with significant unmet medical need. Its assets include Olinciguat and Praliciguat. The Company has entered into an exclusive license option agreement for its vascular soluble guanylate cyclase (sGC) stimulator, olinciguat. Praliciguat is an oral, once-daily, systemic sGC stimulator that is licensed to Akeibia Therapeutics, Inc and is being advanced in rare kidney disease.

Key people

Regina Graul
President, Chief Executive Officer, Director
Rhonda M. Chicko
Chief Financial Officer
Errol De Souza
Independent Chairman of the Board
Peter M. Hecht
Director
Michael J. Higgins
Independent Director
Steven E. Hyman
Independent Director
Dina Katabi
Independent Director
Click to see more

Key facts

  • EPIC
    CYCN
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US23255M2044
  • Market cap
    $9.47m
  • Employees
    1
  • Shares in issue
    3.37m
  • Exchange
    NASDAQ
  • Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.